You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search
Hepatitis C News Articles
Telaprevir Improves Hepatitis C Treatment Response
June 28, 2011
HCV Drug TMC649128 Enters Phase 1b Trial
June 28, 2011
Coffee Improves Response to Hepatitis C Treatment
June 21, 2011
Causes of Death Among People with Hepatitis B and C
June 17, 2011
Vertex Licenses Alios HCV Protease Inhibitors
June 17, 2011
Sitges Meeting Discusses European Access to New Hepatitis C Drugs
June 17, 2011
HCV Protease Inhibitor Danoprevir Promising in Early Trial
June 14, 2011
PSI-7977 Trial Adds New Regimens
June 14, 2011
Updated PegIntron Label Psychiatric Warning
June 14, 2011
BI201335 Shows Potent Activity against HCV
June 3, 2011
Prolonged Entecavir for Slow Responders
June 3, 2011
PSI-7977 + BMS-790052 Trial for Hepatitis C
June 3, 2011
Boceprevir (Victrelis) Patient Assistance Program
May 31, 2011
Telaprevir (Incivek) Patient Assistance Program
May 31, 2011
Caffeine and Liver Disease in People with Hepatitis C
May 31, 2011
Telaprevir (Incivek) Approved for Hepatitis C
May 24, 2011
FDA OKs New Abbott HCV Test
May 24, 2011
European Committee Recommends Boceprevir (Victrelis)
May 20, 2011
TMC435 Boosts Hepatitis C Post-Treatment Response
May 20, 2011
Quality of Life for Children on Hepatitis C Treatment
May 20, 2011
Boceprevir (Victrelis) Approved for Hepatitis C
May 17, 2011
DHHS Releases Viral Hepatitis Action Plan
May 17, 2011
Screen for HCV Based on Age, Not Risk Factors
May 13, 2011
Is Hepatitis C Rising among Young People?
May 13, 2011
Longer Interferon Treatment Raises Hepatitis C Cure Rate
May 10, 2011
EASL Releases New Hepatitis C Clinical Practice Guidelines
May 6, 2011
FDA Committee Unanimously Recommends Telaprevir (Incivek)
May 3, 2011
Boceprevir for HCV Wins Unanimous FDA Committee Recommendation
April 29, 2011
BI 201335 for Hepatitis C Moves into Phase 3 Trials
April 29, 2011
Viral Load, HIV Status, but not IL28B Predict Perinatal HCV Transmission
April 29, 2011
Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
April 26, 2011
Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C
April 26, 2011
FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
April 22, 2011
Tegobuvir Works Well in Triple and Quad Regimens for HCV
April 22, 2011
Boosted Danoprevir Improves Response in Prior Null Responders
April 19, 2011
Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C
April 15, 2011
BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
April 8, 2011
BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
April 8, 2011
First Sustained Response Data for Polymerase Inhibitor Mericitabine
April 5, 2011
Polymerase Inhibitor PSI-7977 Works Well with Interferon or Companion Drug
April 5, 2011
Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
April 5, 2011
Pegylated Interferon Lambda Boosts Response with Fewer Side Effects
April 5, 2011
Telbivudine Label Adds Resistance Warning
April 5, 2011
Telaprevir Combo Works for HCV Patients with Prior Treatment Failure
April 1, 2011
Boceprevir Improves Response to Interferon-Based HCV Therapy
April 1, 2011
Boceprevir Helps Hepatitis C Patients with Cirrhosis
April 1, 2011
4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
April 1, 2011
Statin Boosts Response to Pegylated Interferon/Ribavirin
April 1, 2011
Gene Regulation Mechanism Promotes Liver Cancer
March 29, 2011
TAG Pipeline Report Outlines Future of Hepatitis C Treatment
March 25, 2011
Early Menopause Linked to Poor Hepatitis C Treatment Response
March 25, 2011
FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir
March 18, 2011
New Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C
March 18, 2011
HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
March 15, 2011
U.S. Hepatitis C Incidence Declined 10-fold Over 2 Decades
March 11, 2011
HCV Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status, TMC649128 Enters Phase 1a Trial
CROI 2010
March 4, 2011
Tibotec Starts Phase 3 Clinical Trials of HCV Protease Inhibitor TMC435
February 25, 2011
FDA Approves HCV Rapid Antibody Test for Fingerstick Blood Samples
February 25, 2011
Treatment of Recurrent Hepatitis C after Liver Transplantation
February 18, 2011
Little Change in Hepatitis C Risk among Injection Drug Users
February 11, 2011
San Francisco Hepatitis C Task Force Issues Recommendations
February 11, 2011
Hepatitis C Patients May Have Increased Risk of Stroke
February 1, 2011
Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
February 1, 2011
Peretinoin Improves Hepatocellular Carcinoma in People with Mild Liver Impairment
January 28, 2011
HCV Protease Inhibitor Telaprevir Will Get Priority Review in U.S. and Canada
January 25, 2011
Body Weight May Not Affect Hepatitis C Treatment if Ribavirin Dose Is Adequate
January 25, 2011
HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study
January 21, 2011
Nucleic Acid Testing Identifies Hepatitis B Virus Sooner in Blood Donors
January 21, 2011
HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and Europe
January 14, 2011
Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C
January 14, 2011
Peregrine Starts Phase 2 Trial of Monoclonal Antibody Hepatitis C Treatment
January 14, 2011
Anemia during Hepatitis C Treatment Predicts Sustained Response to Pegylated Interferon/ribavirin
January 11, 2011
Pharmasset Starts Trial of HCV Polymerase Inhibitor PSI-7977 without Interferon
January 11, 2011
Vertex Ends Clinical Trial Arm Testing Dual Telaprevir Plus VX-222 Regimen
January 7, 2011
Experts Devise Roadmap for Development of Direct-acting Hepatitis C Drugs
January 7, 2011
Pre-treatment with Ribavirin Improves Response to Interferon-based Therapy for Hepatitis C
December 14, 2010
Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease
December 14, 2010
Hepatitis C Experts Sought for FDA Advisory Committee
December 10, 2010
Pegylated Interferon Lambda for Hepatitis C Produces Good Response with Minimal Blood Toxicity
December 10, 2010
Menopause and Obesity Predict HCV Relapse after Interferon-based Therapy
December 10, 2010
Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
December 3, 2010
Vertex Completes FDA Submission of Telaprevir New Drug Application
November 19, 2010
Interim Results Show TMC435 Works Well in Treatment-experienced Hepatitis C Patients
November 19, 2010
Do IL28B Gene Variations Affect Liver Disease Progression in People with Hepatitis C?
November 19, 2010
IL28B Gene Patterns and Liver Transplant Outcomes in Hepatitis C Patients
November 19, 2010
AASLD 2010 - Talking Slides™ Update
November 16, 2010
Directing-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
November 16, 2010
Higher Doses May Overcome Poor Response to Interferon in Hepatitis C Patients with Unfavorable IL28B Gene Pattern
November 12, 2010
Preliminary Results Show Promising Response to Therapeutic Hepatitis C Vaccine GI-5005
November 12, 2010
Early Analysis Finds Good Outcomes with Once-daily Dosing of HCV Protease Inhibitor TMC435
November 5, 2010
Sustained Response to Hepatitis C Therapy Is Key to Improved Survival after Liver Transplantation
November 5, 2010
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration of Treatment
November 5, 2010
Telaprevir Increases Sustained Response Rates and Shortens Treatment Duration for Newly Treated Hepatitis C Patients
November 5, 2010
Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients
October 29, 2010
FDA Approves Roche's Second-generation Hepatitis C Viral Load Test
October 29, 2010
AASLD Liver Meeting Offers On-Site Registration This Week
October 29, 2010
Can Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
October 26, 2010
Direct-acting Drugs Danoprevir plus RG7128 Suppress HCV without Interferon
October 26, 2010
Weight-based Taribavirin Works as Well as Ribavirin for Chronic Hepatitis C, but Causes Less Anemia
October 15, 2010
Hepatitis C Virus Causes Brain Inflammation Leading to Neuron Injury
October 15, 2010
Roche Acquires Rights to InterMune HCV Protease Inhibitor Danoprevir
October 8, 2010
AASLD and Trust for America's Health Call for Action on Hepatitis B and C
October 8, 2010
Weight-based Taribavirin Works as Well as Ribavirin for Chronic Hepatitis C, but Causes Less Anemia
October 1, 2010
Three-quarters of People with Hepatitis C in the U.S. Have Hard-to-treat Genotype 1
October 1, 2010
October 1 Is AASLD Liver Meeting Discount Registration Deadline
September 28, 2010
Vancouver Hepatitis C Treatment Program for Injection Drug Users Proves Popular and Successful
September 28, 2010
October 1 Is AASLD Liver Meeting Discount Registration Deadline
September 28, 2010
Vancouver Hepatitis C Treatment Program for Injection Drug Users Proves Popular and Successful
September 28, 2010
First MicroRNA Hepatitis C Therapy Enters Phase 2 Clinical Development
September 24, 2010
Heterosexual Sex Not a Major Risk Factor for Hepatitis C Virus Transmission
September 21, 2010
FDA Issues Guidance for Development of Direct-acting Antiviral Drugs for Hepatitis C
September 17, 2010
Natural history of Hepatitis C Acquired through Injection Drug Use
September 14, 2010
Telaprevir Combination Therapy Boosts Sustained Response Rates for Previously Treated Hepatitis C Patients
September 10, 2010
FDA Suspends Trials of Experimental HCV Regimen IDX184 plus IDX320 Due to Liver Toxicity Concerns
September 10, 2010
Week 4 Rapid Virological Response Predicts Sustained Response to Interferon-based Hepatitis C Treatment
September 4, 2010
People Who Naturally Clear Hepatitis C Virus Have Lower Risk of Death than Chronic Patients
August 31, 2010
Pegylated Interferon plus Ribavirin Has High Sustained Response Rates in Children with Hepatitis C
August 31, 2010
IL28B Gene Pattern May Influence Susceptibility to Hepatitis C Virus Genotypes
August 31, 2010
Only Fittest Hepatitis C Virus Strains Re-infect New Liver after Transplantation
August 27, 2010
Protease Inhibitor TMC435 Shows Potent and Sustained Efficacy for Genotype 1 Chronic Hepatitis C
August 24, 2010
Silymarin Milk Thistle Extract May Inhibit Hepatitis C Virus Entry into Cells
August 20, 2010
International Study Links Tattoos with Higher Risk of Hepatitis C
August 17, 2010
HCV Polymerase Inhibitor PSI-7977 Receives FDA Fast Track Designation
August 17, 2010
Addition of HCV Protease Inhibitor Telaprevir Can Shorten Interferon-based Hepatitis C Treatment
August 17, 2010
HCV Protease Inhibitor Boceprevir Increased Sustained Response to
Interferon-based Therapy in Phase 3 Studies

August 6, 2010
Hepatitis C Virus Prevalence Has Decreased among U.S. Blood Donors Since the Early 1990s
August 6, 2010
Combination Therapy with HCV Polymerase Inhibitor ANA598 Produces 12-week Sustained Response in Small Study
August 6, 2010
Chronic Hepatitis C Virus Infection Is Associated with Early Atherosclerosis
July 30, 2010
Pharmasset Starts New Phase 1b Clinical Trial of HCV Polymerase Inhibitor PSI-938
July 30, 2010
Hope Against Hepatitis C
July 30, 2010
Hepatitis C Virus Can Remain Viable for Months in a Liquid Environment at Low Temperatures
July 20, 2010
Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
July 20, 2010
Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
July 20, 2010
Eiger HCV NS4B Inhibitor Exhibits Synergy with Experimental HCV Protease Inhibitors
July 9, 2010
Consensus Interferon (Infergen) Label Changed to Include Data on Dosing with Ribavirin
July 9, 2010
Immune Cells Show Signs of Senescence after Liver Transplantation
July 9, 2010
Chronic Hepatitis C Linked to Increased Risk of Kidney Cancer
July 6, 2010
Sustained Response to Antiviral Therapy Prevents Esophageal Varices in Hepatitis C Patients with Cirrhosis
July 6, 2010
FDA Approves First Rapid Hepatitis C Virus Antibody Blood Test
July 2, 2010
Treating Hepatitis C in People with Compensated Cirrhosis Is Most Cost-effective Approach
July 2, 2010
House of Representatives Holds Hearing on the "Secret Epidemic" of Viral Hepatitis
July 2, 2010
Blood-boosting Adjuvant Therapies Can Improve Response to Interferon-based Treatment for Hepatitis C
July 2, 2010

Reports from Recent
Hepatitis-related
Research Conferences

Noimage

Noimage

Boceprevir + Pegylated
  
Interferon + Ribavirin

Telaprevir + Pegylated
  
Interferon + Ribavirin
Pegasys + Copegus
PEG-Intron + Rebetol
Infergen + Ribavirin
Intron A + Rebetol
Roferon A + Ribavirin
Experimental Treatments
Treatment Guidelines
Cirrhosis
Fibrosis
Hepatocellular Carcinoma
Liver Transplantation
Liver Biopsy
Steatosis
Anemia
Children / Infants / Women
Experimental Treatments
FAQs About Hepatitis C
Genotypes
Insulin Resistance / Diabetes
Sustained Viral Response
Tests for HCV
Vaccines for HCV